TG Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on TG Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how TG Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with TG Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on TG Therapeutics Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4286010A1 | Application | Anti-cd20-antikörperzusammensetzungen | A61P37/00; C07K16/2887; C07K2317/14; C07K2317/41 | December 06, 2023 |
| EP4286413A1 | Application | Anti-cd20-antikörperzusammensetzungen | A61K2039/545; A61K47/02; A61P37/00; C07K16/2887; C07K2317/14; C07K2317/41; C07K2317/732; C07K2317/734 | December 06, 2023 |
| EP4286414A1 | Application | Anti-cd20-antikörperzusammensetzungen | A61K2039/545; A61K31/138; A61K31/167; A61K31/573; A61P37/00; C07K16/2887; C07K2317/14; C07K2317/41; C07K2317/732; C07K2317/734; C07K2317/92 | December 06, 2023 |
| US11814439B1 | Grant | Anti-cd20 antibody compositions | A61K2039/545; A61K31/138; A61K31/167; A61K31/573; C07K16/2887; C07K2317/41; C07K2317/732; C07K2317/734; C07K2317/92 | November 14, 2023 |
| US11807689B1 | Grant | Anti-cd20 antibody compositions | A61K47/02; C07K16/2887; C07K2317/732; C07K2317/734 | November 07, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer